Dominique Costantini
Founder bei OSE IMMUNOTHERAPEUTICS
Profil
Dominique Costantini is the founder of Valerio Therapeutics SA (founded in 1997), Orphan Synergy Europe-Pharma SA (founded in 2004), OSE Pharmaceuticals (founded in 2012), and OSE Immunotherapeutics SA (founded in 2004).
She held the title of Chief Executive Officer at Valerio Therapeutics SA in 2011, Chief Executive Officer at Orphan Synergy Europe-Pharma SA in 2012, and Chief Executive Officer at OSE Pharmaceuticals.
Currently, Dr. Costantini is the Chairman & Chief Development & Strategy at OSE Immunotherapeutics SA. She is also currently working as a Director at Only For Children Pharmaceuticals SA and as an Independent Director at Smart Immune SAS.
In the past, she has worked as the Chairman at CarThera SAS, Independent Director at Theradiag SA, Independent Director at AB Science SA, Independent Director at Sensorion SA, Independent Director at Theranexus SA from 2017 to 2020, Independent Director at Abivax SA from 2015 to 2018, and as a Director at Horama SA. Dr. Costantini also worked at Sanofi as a Principal.
She holds a doctorate degree from Université de Paris 5 René Descartes.
Aktive Positionen von Dominique Costantini
| Unternehmen | Position | Beginn |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Founder | 17.11.2004 |
| Only For Children Pharmaceuticals SA | Director/Board Member | - |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Director/Board Member | - |
Ehemalige bekannte Positionen von Dominique Costantini
| Unternehmen | Position | Ende |
|---|---|---|
| THERANEXUS | Director/Board Member | 01.01.2020 |
| ABIVAX | Director/Board Member | 21.12.2018 |
| VALERIO THERAPEUTICS | Chief Executive Officer | 29.06.2011 |
| OSE Pharmaceuticals | Chief Executive Officer | - |
| SENSORION | Director/Board Member | - |
Ausbildung von Dominique Costantini
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| SANOFI | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| AB SCIENCE | Health Technology |
| SENSORION | Health Technology |
| THERANEXUS | Health Technology |
| ABIVAX | Health Technology |
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Theradiag SA
 Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
| Université de Paris 5 René Descartes | Consumer Services |
CarThera SAS
 CarThera SAS Medical SpecialtiesHealth Technology CarThera SAS develops ultrasound based medical devices to treat brain disorders. The firm offers SonoProbe and SonoCloud. The company was founded by Alexandre Carpentier on February 8, 2010 and is headquartered in Paris, France. | Health Technology |
Orphan Synergy Europe-Pharma SA
 Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
| Only For Children Pharmaceuticals SA | |
| OSE Pharmaceuticals | |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Health Technology |
